[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536208":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":116,"collaborators":119,"id":127,"slug":128,"hasResults":129,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":39,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":135,"minAge":136,"maxAge":39,"enrollmentInfo":137,"targetDuration":39,"studyType":140,"phases":141,"briefSummary":143,"conditions":144,"keywords":39,"overallStatus":48,"whyStopped":39,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"Tulane University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral Multi-Dose Metronidazole","EXPERIMENTAL","Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men",[13],"Drug: Metronidazole 500 mg",{"label":15,"type":10,"description":16,"interventionNames":17},"Single-Dose Secnidazole","Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men",[18],"Drug: Secnidazole 2000 MG",[20,26],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Metronidazole 500 mg",[9],[25],"FLAGYL",{"type":21,"name":27,"description":16,"armGroupLabels":28,"otherNames":29},"Secnidazole 2000 MG",[15],[30],"SOLOSEC",[32],{"name":33,"affiliation":5,"role":34},"Patricia Kissinger, PhD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":33,"role":37,"phone":38,"phoneExt":39,"email":40},"CONTACT","504-988-7320",null,"kissing@tulune.edu",{"name":42,"role":37,"phone":43,"phoneExt":39,"email":44},"Christina Muzny, MD","205-975-3298","cmuzny@uabmc.edu",[46,68,81,99],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"University of Alabama at Birmingham [UAB] Gynecology Clinics","RECRUITING","Birmingham","Alabama","25233","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-86.80249,33.52066,{"lat":58,"lon":57},[61,65],{"name":62,"role":37,"phone":63,"phoneExt":39,"email":64},"Stephanie Clevenger","205-934-0877","slangan@uabmc.edu",{"name":66,"role":67,"phone":39,"phoneExt":39,"email":39},"Janeen Arbuckle","SUB_INVESTIGATOR",{"facility":69,"status":48,"city":49,"state":50,"zip":70,"country":52,"countryCode":53,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"UAB Sexual Health Research Clinic [SHRC]","35205",{"type":55,"coordinates":72},[57,58],{"lat":58,"lon":57},[75,79],{"name":76,"role":37,"phone":77,"phoneExt":39,"email":78},"Saralyn Richter","205-934-8166","srichter@uabmc.edu",{"name":80,"role":34,"phone":39,"phoneExt":39,"email":39},"Christina Muzny",{"facility":82,"status":83,"city":84,"state":85,"zip":86,"country":52,"countryCode":53,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Segal Trials Healthcare Clinical Data, Inc. 1065 NE 125th St. Suite 417 North Miami, FL 33161","NOT_YET_RECRUITING","North Miami","Florida","33161",{"type":55,"coordinates":88},[89,90],-80.18671,25.89009,{"lat":90,"lon":89},[93,97],{"name":94,"role":37,"phone":95,"phoneExt":39,"email":96},"Dimary Rivera","305-722-8444","drivera@segaltrials.com",{"name":98,"role":67,"phone":39,"phoneExt":39,"email":39},"Steven Chavoustie",{"facility":100,"status":48,"city":101,"state":102,"zip":103,"country":52,"countryCode":53,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"LSU-CrescentCare Sexual Health Center","New Orleans","Louisiana","70119",{"type":55,"coordinates":105},[106,107],-90.07507,29.95465,{"lat":107,"lon":106},[110,114],{"name":111,"role":37,"phone":112,"phoneExt":39,"email":113},"Catherine Cammarata","504-568-4132","CCamma@lsuhsc.edu",{"name":115,"role":67,"phone":39,"phoneExt":39,"email":39},"Rebecca Lillis",{"type":34,"investigatorFullName":117,"investigatorTitle":118,"investigatorAffiliation":5,"oldNameTitle":39,"oldOrganization":39},"Patricia Kissinger","Principal Investigator",[120,122,124],{"name":121,"class":6},"University of Alabama at Birmingham",{"name":123,"class":6},"Louisiana State University Health Sciences Center in New Orleans",{"name":125,"class":126},"Healthcare Clinical Data","UNKNOWN","100536208","phase-4-refining-treatment-options-for-trichomonas-vaginalis-infection-a-comparative-analysis-of-metronidazole-and-secnidazole-100536208",false,"NCT06261840","Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole","Refining Treatment Options for Trichomonas Vaginalis Infection in Women and Men: A Comparative Analysis of Oral Multi-Dose Metronidazole and Single-Dose Secnidazole","Inclusion Criteria:\n\n* Women and men aged 18 years or older of any race\u002Fethnicity will be included in the study.\n* Participants must have either a positive T. vaginalis rapid antigen test (OSOM), or wet mount microscopy with motile trichomonads, or nucleic acid amplification test (NAAT) urinalysis or Pap smear positive for TV within two weeks of available results (and have not yet been treated) that is confirmed by repeat T. vaginalis NAAT testing at study enrollment,\n* Willing and able to provide and understand informed consent to comply with the study protocol,\n* Have a method of contact (either phone, email or social media),\n* Be willing to be randomized.\n\nExclusion Criteria:\n\n* Pregnant\u002Flactating or seeking to be pregnant\n* Have been treated for with a 5-nitroimidazole (i.e. Metronidazole (MTZ), tinidazole (TDZ), or secnidazole \\[SEC\\]) in the last 28 days\n* Used intravaginal boric acid or any other intravaginal treatment for T. vaginalis in the last 14 days\n* Have a history of a type 1 hypersensitivity reaction to 5-nitroimidazole medications\n* Are taking phenytoin (Dilantin) and\u002For warfarin (Coumadin) due to drug-drug interactions with oral MTZ\n* Use of medications which may alter the metabolism of MTZ including Lithium and barbiturates (amobarbital, butalbital, methohexital, phenobarbital, pentobarbital, primidone, secobarbital)\n* Have been previously enrolled in the study",true,"ALL","18 Years",{"count":138,"type":139},1200,"ESTIMATED","INTERVENTIONAL",[142],"PHASE4","This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.",[145,146],"Trichomonas Vaginitis","Bacterial Vaginitis","2026-05-04",{"date":149,"type":150},"2026-05-06","ACTUAL",{"date":152,"type":150},"2025-05-06",{"date":154,"type":139},"2029-07-31",{"name":5,"class":6},4]